The Impact of Hyperkalemia-Induced ECG and ECHO Findings on Early and Late Mortality in Patients With Chronic Kidney Disease

What this Trial Is About

This research investigates patients with chronic kidney disease (CKD) who have an estimated glomerular filtration rate (eGFR) below 60 mL/min/1.73 m² and present to the emergency department with isolated high potassium levels (hyperkalemia). The study aims to examine electrocardiogram (ECG) and echocardiography (ECHO) findings in these patients and their association with early and late mortality. Researchers will compare these findings to existing literature to better understand the cardiac effects of hyperkalemia in CKD patients. Participants will form a single group of patients diagnosed with hyperkalemia. Blood samples will be taken to measure potassium levels, followed by ECG and ECHO tests before and after treatment. The ECHO is performed by an experienced physician who is not involved in treatment decisions. The study does not interfere with any medical interventions, which remain under the care of the responsible physician. Throughout the study, data from ECG, ECHO, and laboratory tests will be collected and analyzed. Mortality will be tracked at 24 hours, 7 days, and 30 days after enrollment, excluding other causes of death. The main outcome is to observe changes in echocardiographic findings over 30 days. This study also explores the potential link between cardiac imaging changes due to hyperkalemia and patient survival, offering insight into the usefulness of combined ECG and ECHO monitoring.

Chronic Kidney Disease, Hyperkalemia and Echocardiographic Changes